

State of Illinois Drugs and Therapeutics Advisory Board

Minutes for October 10, 2024, Meeting

- I. Dr. Patel opened the meeting at 8:33am.
- II. Roll Call was taken.
- III. No conflicts of interest.
- IV. The August 1, 2024, meeting minutes were unanimously approved.
- V. PDL Drug Appeals

A. Product: Rinvoq

Presented by: Dr. Manish Jain/Neelesh Patel-AbbVie/Dr. Jen Phillips-UIC

Presented Material Highlights:

- A number of indications are approved for Rinvoq who have inadequate response to TNF blockers.
- Warning and precautions are class associated.
- JAK inhibitors are addressed in the guidelines as primary or secondary therapy.
- Only JAK inhibitor with 8 different indications.
- Oral-both tablet and liquid.
- Only JAK approved for Crohn's Disease.
- Dr. Jain spoke to head-to-head trial with Humira and its superiority.
- He has not seen class toxicity issues.
- Used in refractory patients.
- Rapid relief for Atopic dermatitis patients.
- Moving to preferred would facilitate faster move to product.
-

Discussion Highlights:

- Olumient is only available at lower dose here in the US.
- Rinvoq has both tabs and liquid.
- Available for more indications than others in the class

Motion: Dr. Vergara-Rodriguez moved to make Rinvoq preferred with PA.

Second: Dr. Florence

Motion passed without dissent. Dr. Goyal abstained.

B. Product: Adbry

Presented by: Dr. Jen Phillips, UIC

Presented Material Highlights:

- Approved for those not responsive to topical treatments for Atopic Dermatitis.
- Dupixent is preferred now and has broader indications.
- Cosentyx is also preferred with PA.
- Auto-injector and prefilled syringe.
- Initial treatment must begin at the doctor's office.
- Guidelines recommend in moderate to severe Atopic dermatitis.

Discussion Highlights:

- Adbry is only Atopic dermatitis.
- Cosentyx is not for Atopic Dermatitis.
- Although the guidelines recommend either Adbry or Dupixent, a secondary comment seems to favor Dupixent over Adbry.
- Rinvoq is also indicated for Atopic Dermatitis and in a head-to-head study was more effective.

Motion: Dr. Patel moved to leave Adbry non-preferred

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

VI. New Drug Appeals-Dr. Jen Phillips

A. Glatiramer

Presented Material Highlights:

- All products are equivalent.

Discussion Highlights:

- Copaxone is the brand.
- Glatiramer is the generic
- Glatopa is a branded generic.
- All made by different manufacturers.
- No actual difference
- Board would like Department to make a financial decision on what is most cost-effective since they are therapeutically equivalent.

Motion: Garry Moreland moved that the products are equivalent, and the Department should make the most cost-effective decision.

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

VII. Class Reviews

a. Topic: HIV Single Tablet Regimens

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Several treatment classes
- Combination treatments are also available.
- Guidelines note regimens should be individualized.
- Initial treatment recommendations are single tablet regimens.
- Biktarvy is rated 1A.
- Triumeq is no longer recommended as an initial therapy due to labs that must be done.
- Treatment experienced therapy is highly individualized.
- Salvage regimens are reserved for those with resistance.

Discussion Highlights:

- Cabenuva has been a huge innovation for specialists.
- Adherence to long-acting agents is better.
- People are on so many different individualized treatment regimens.
- Initial patients generally start on Biktarvy or Dovato.
- Would like to see almost all as preferred.
- Goal is to get zero.
- If a person is stabilized on any regimen they should not be changed.
- These are not prescribed without experience or referral.
- New concern in HIV is metabolic issues leading to cardiovascular disease.

Motion: Dr. Vergara-Rodriguez moved to make Cabenuva, Pifeltro, PrezcoBix, Juluca and Cimduo preferred

Second: Dr. Patel

Motion passed without dissent.

Motion: Dr. Vergara-Rodriguez moved that Rukobia be made preferred with PA

Second: Dr. Patel

Motion passed without dissent.

Board recommends a full review of all HIV products.

VIII. New Drug Initial Reviews

A. Product: Iqirvo

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Indicated for Primary Biliary cholangitis with Urodeoxycholic acid (UCDA) or a monotherapy.
- Used in those that are not fully responsive to UCDA itself.

- Monitor liver function.
- Fetal harm is possible so contraceptive use is recommended.
- Guidelines recommend UCDA but have not been updated since 2021.
- Approved via Accelerated Approval.
- Chad Sanders for Ipsen testified.
- Rare disease 30-40 per 100,000.
- Most prevalent in women between 40-60 years old.
- A correction to Livdelzi generic name was made.
- Has not been looked at in comparison to fenofibrate and UDCA which is used in practice today or Livdelzi.

Discussion Highlights

- Would like to know UCDA utilization and fenofibrate as well.
- Ocaliva is also available as a treatment.
- UDCA is first line others should be used second line.
- Perhaps look at all drugs used to treat PBC as a class.

Motion: Dr. Patel moved to table until further information on other products used to treat PBC currently.

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

B. Product: Winrevair

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Indicated for Pulmonary Arterial Hypertension (PAH).
- Different mechanism on action than others in the class.
- Labs are recommended prior to starting Winrevair.
- Continue to monitor labs as dose is titrated.
- Most users are on multiple drug treatment.
- Can cause serious blood hemoglobin and platelet changes.
- No guideline updates since 2019.

Discussion Highlights:

- Very complicated disease process.
- There are several agents available for this disease.
- It would be nice to have some anecdotal experience with this before making preferred.
- David Shin-Merck testified.
- Unique mechanism of action.
- Added to background therapy.
- Long term data is not available but a trial is underway.
- Some patients have up to 7 years of data .

Motion: Dr. Patel moved to make Non-preferred
Second: Dr. Florence
Motion passed with no dissent.

C. Product: Zoryve

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Indicated for plaques psoriasis and Atopic Dermatitis.
- Available in 2 strengths.
- This is a topical cream.
- Only short-term data is available at this time.

Discussion Highlights:

- This a form of Vitamin D.
- Steroid free.
- Patients prefer a cream over a solution.
- For mild to moderate disease.
- Are patients getting what they need?
- Majority of patients want to use the cream.
- Lots of vehicles for treatment available (cream, solution, oint, etc.).
- Proven safe.

Motion: Dr. Patel moved to leave non-preferred and come back to this class at a later date
Second: Dr. Florence
Motion passed without dissent.

IX. Public Testimony

Speaker	Product	Organization
Dr. Manish Jain	Rinvoq	AbbVie
Neelesh Nadkarni	Rinvoq	AbbVie
Chase Williams	HIV products	Gilead
David Shin	Winrevair	Merck
Chad Sanders	Iqirvo	Ipsen

- X. Provider Review Request
- None at this meeting.

- XI. Future Agenda Preview
 - January 9, 2024
 - Topic HIV full class review
- XII. HFS Update
- XIII. Department Update-Jose Jimenez, BPAS Bureau Chief
 - 3.5M recipients
 - Thanks to board members for their commitments.
 - Informed the Board that Sheri Dolan is leaving the Department January 1, 2025.
- XIV. Adjournment-Dr. Patel adjured the meeting at 10:47 am.

Panelist List

- 1. Alyssa Stephenson
- 2. Sheri Dolan
- 3. **Arvind Goyal**
- 4. Heather Freeman
- 5. **Janet Albers**
- 6. Jennifer Dewitt
- 7. Jose Jimenez
- 8. **Garry Moreland**
- 9. Claudia Colombo
- 10. **Maurice Shaw**
- 11. **Nicole Florence**
- 12. **Pamela Vergara-Rodriguez**
- 13. Mary Moody
- 14. **Mahesh Patel**
- 15. Steve Sproat
- 16. **Thomas Dorn**
- 17. Jen Phillips

Attendee List

1. A Meizlik
2. Bob Baranick
3. Brooks, Kimbra
4. Bryan Dillon
5. Call in User 2
6. **Chad Sanders**
7. **Chase Williams**
8. Chiamaka Osuji
9. Chris Tanaka
10. Clemice Hurst
11. Dan Calloway
12. **David Shin**
13. Doug Johnson
14. Drew Halbur
15. Gary Parenteau
16. Greg Kitchens Artia Solutions
17. Hassan, Sakib
18. Huzefa Master
19. Jeff Knappen
20. Jerry Lubben
21. Jim Sharp
22. Jon Vlasnik
23. Kelly
24. Kenneth Ring
25. Kevin
26. Leanne Shu
27. **Manish Jain**
28. Mary Kaneaster

29. Matt Grewe
30. Michele Shirley – Indivior
31. Nadeen Israel
32. **Neelesh P Nadkarni**
33. Nichole Palusinki
34. Patrick Boland
35. Paul Huber
36. Phil Lohec Viatrix
37. Ryan Segroves
38. Shana Walko
39. Stacey Repotski
40. Steve Patterson
41. Suzana Tsang
42. Teresa Blair – Ipsen
43. Thomas Vayalil
44. Tonya Duffina